Naratriptan Zentiva (Naratriptan Hydrochloride)

Naratriptan Hydrochloride, the active ingredient in Naratriptan Zentiva, is a Triptan (5‑HT1B/1D receptor agonist) presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks in adults and works by targeting serotonin receptors to alleviate headache pain and associated symptoms.

GNH USA supplies Naratriptan Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide.

Naratriptan Zentiva, a triptan class medication, is used for the acute management of migraine.

- Migraine (with or without aura): provides rapid relief of headache pain and associated symptoms during an acute attack. - Migraine with aura: helps reduce the intensity of visual disturbances when taken early in the episode. - Migraine without aura: alleviates throbbing head pain, nausea and photophobia associated with an attack.

Naratriptan Zentiva may cause a range of adverse reactions. Most are mild and transient.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Dizziness: sensation of light‑headedness. - Fatigue: feeling unusually tired. - Dry mouth: reduced salivation. - Tingling: paresthesia in extremities. - Drowsiness: increased sleepiness.

Serious or Rare Side Effects: - Chest discomfort or pain: possible cardiac ischemia. - Serotonin syndrome: agitation, hyperthermia, muscle rigidity. - Severe allergic reaction: rash, swelling, breathing difficulty. - Hypertension: sudden rise in blood pressure. - Cardiac arrhythmia: irregular heart rhythm. - Vasospasm of coronary arteries: reduced blood flow to the heart.

Before prescribing Naratriptan Zentiva, clinicians should consider several safety factors.

- Cardiovascular assessment: avoid in patients with known coronary artery disease, uncontrolled hypertension or history of myocardial infarction. - Drug history review: caution if patient uses other serotonergic agents such as SSRIs, SNRIs or MAO inhibitors. - Age considerations: safety in children and adolescents has not been established. - Pregnancy and lactation: use only if the potential benefit outweighs the risk; data are limited. - Renal or hepatic impairment: dose adjustment may be required based on clinical judgment. - Store at ambient temperature: keep below 25 °C, retain in the original packaging, protect from moisture and direct sunlight.

Naratriptan Zentiva can interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension and serotonin syndrome. - Other triptans or ergot derivatives: additive vasoconstrictive effects. - SSRIs/SNRIs: increased potential for serotonin syndrome.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: may enhance blood pressure‑lowering effect. - CYP1A2 inhibitors (e.g., fluvoxamine): may increase naratriptan plasma levels. - Oral contraceptives: possible alteration of migraine pattern; monitor efficacy.